Serum level of TSGF,CA242 and CA19-9 in pancreatic cancer

被引:29
作者
Jing-Ting Jiang Chang-Ping Wu Hai-Feng Deng Ming-Yang Lu Jun Wu Hong-Yu Zhang Wen-Hui Sun Mei Ji Department of Tumor Biological Treatment
机构
关键词
TSGF; Serum level of TSGF; CA242 and CA19-9 in pancreatic cancer; CA;
D O I
暂无
中图分类号
R735.9 [胰腺肿瘤];
学科分类号
100214 ;
摘要
AIM:To establish a method to detect the expression of thetumor specific growth factor TSGF,CA242 and CA19-9 in serumand evaluate their value in diagnosis of pancreatic cancer.METHODS:ELISA and Biochemical colorimetric assay wereused to detect the serum content of TSGF,CA242 andCA19-9 in 200 normal cases,52 pancreatitis patients and96 pancreatic cancer patients.RESULTS:The positive likelihood ratios of TSGF,CA242and CA19-9 were 5.4,12.6 and 6.3,respectively,and theirnegative likelihood ratios were 0.10,0.19 and 0.17,respectively.With single tumor marker diagnosed pancreaticcancer,the highest sensitivity and specificity of TSGF were91.6% and 93.5%.In combined test with 3 markers,whenall of them were positive,the sensitivity changed to 77.0%and the specificity and the positive predictive value were100%.The levels of TSGF and CA242 were significantly higherin the patients with pancreatic cancer of head than those inthe patients with pancreatic cancer of body,tail and wholepancreas,but the expression of CA19-9 had no correlationwith the positions of the pancreatic cancer.The sensitivityof TSGF,CA242 and CA19-9 was increased with the progressin stages of pancreatic cancer.In stage Ⅰ,the sensitivity ofTSGF was markedly higher than CA242 and CA19-9.CONCLUSION:The combined use of TSGF,CA242 and CA19-9 expressions can elevate the specificity for pancreatic cancerdiagnosis.And it shows that it plays an important role todifferentiate positions and tissue typing.It is a forepartdiagnosis for the pancreatic cancer by combination checking.There is very important correlation between the three markersand the pancreatic cancer.
引用
收藏
页码:1675 / 1677
页数:3
相关论文
共 50 条
  • [21] Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma
    Wang, Wei
    Chen, Xiao-Long
    Zhao, Shen-Yu
    Xu, Yu-Hui
    Zhang, Wei-Han
    Liu, Kai
    Chen, Xin-Zu
    Yang, Kun
    Zhang, Bo
    Chen, Zhi-Xin
    Chen, Jia-Ping
    Zhou, Zong-Guang
    Hu, Jian-Kun
    ONCOTARGET, 2016, 7 (23) : 35423 - 35436
  • [22] Serum CA19-9 Levels and Pancreatic Beta Cell Destruction in Type 2 Diabetes Mellitus Patients
    Saif, Mohammad Mansour Saleh
    Al-Asbahy, Waddaah M.
    Al-Fakih, Abdulkawi Ali
    Albadani, Adeeb Mohammed
    BRITISH JOURNAL OF PHARMACEUTICAL RESEARCH, 2016, 14 (06):
  • [23] Serum levels of CA 19-9 in patients with pancreatic cancer and liver cirrhosis
    Kadayifci, A
    Simsek, H
    Usalan, C
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1995, 14 (04) : 435 - 437
  • [24] Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review
    Ballehaninna U.K.
    Chamberlain R.S.
    Indian Journal of Surgical Oncology, 2011, 2 (2) : 88 - 100
  • [25] Characteristics and prognosis of patients with pancreatic adenocarcinoma not expressing CA19-9: Analysis of the National Cancer Database
    Sugawara, Toshitaka
    Franco, Salvador Rodriguez
    Sherman, Samantha
    Kirsch, Michael J.
    Colborn, Kathryn
    Franklin, Oskar
    Ishida, Jun
    Grandi, Samuele
    Al-Musawi, Mohammed H.
    Gleisner, Ana
    Schulick, Richard D.
    Del Chiaro, Marco
    PANCREATOLOGY, 2024, 24 (08) : 1340 - 1347
  • [26] Prognostic Value of Serum Tumor Antigen CA19-9 After Curative Resection of Colorectal Cancer
    Park, In Ja
    Choi, Gyu-Seog
    Jun, Soo Han
    ANTICANCER RESEARCH, 2009, 29 (10) : 4303 - 4308
  • [27] Combined Detection of CEA, CA 19-9, CA 242 and CA 50 in the Diagnosis and Prognosis of Resectable Gastric Cancer
    Tian, Shu-Bo
    Yu, Jian-Chun
    Kang, Wei-Ming
    Ma, Zhi-Qiang
    Ye, Xin
    Cao, Zhan-Jiang
    Yan, Chao
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (15) : 6295 - 6300
  • [28] CEA, CA 242, CA 19-9, CA 72-4 and hCGβ in the diagnosis of recurrent colorectal cancer
    Carpelan-Holmström, M
    Louhimo, J
    Stenman, UH
    Alfthan, H
    Järvinen, H
    Haglund, C
    TUMOR BIOLOGY, 2004, 25 (5-6) : 228 - 234
  • [29] The role of CA-19-9, CA 242 and CEA tumor markers in digestive tract cancer diagnostics
    Hasmik, Vahradyan
    Hasmik, Harutyunyan
    Qnarik, Aleqsanyan
    CLINICAL BIOCHEMISTRY, 2011, 44 (13) : S209 - S209
  • [30] CA125 and CA242 markers' role in colorectal cancer diagnosis and management - a 30 year review
    Ion, Daniel
    Radu, Georgiana
    Paduraru, Dan Nicolae
    Andronic, Octavian
    Bolocan, Alexandra
    ROMANIAN BIOTECHNOLOGICAL LETTERS, 2020, 25 (05): : 1977 - 1983